These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33419847)

  • 21. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
    Ismael G; Hegg R; Muehlbauer S; Heinzmann D; Lum B; Kim SB; Pienkowski T; Lichinitser M; Semiglazov V; Melichar B; Jackisch C
    Lancet Oncol; 2012 Sep; 13(9):869-78. PubMed ID: 22884505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
    Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Venat-Bouvet L; Cany L; Catala S; Khayat D; Gambotti L; Pauporté I; Faure-Mercier C; Paget-Bailly S; Henriques J; Grouin JM;
    Lancet; 2019 Jun; 393(10191):2591-2598. PubMed ID: 31178155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
    Yamashiro H; Iwata H; Masuda N; Yamamoto N; Nishimura R; Ohtani S; Sato N; Takahashi M; Kamio T; Yamazaki K; Saito T; Kato M; Lee T; Kuroi K; Takano T; Yasuno S; Morita S; Ohno S; Toi M;
    Breast Cancer; 2020 Jul; 27(4):631-641. PubMed ID: 32060785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
    van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
    Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study.
    Jacquin JP; Uwer L; Savignoni A; Ferrero JM; Lortholary A; Solub D; Delaporte F; Chalabi N; Pibre S; Belkacemi Y
    Breast; 2020 Feb; 49():1-7. PubMed ID: 31670262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
    Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
    J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
    Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
    Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.
    Palmieri C; Macpherson IR; Yan K; Ades F; Riddle P; Ahmed R; Owadally W; Stanley B; Shah D; Gojis O; Januszewski A; Lewanski C; Asher R; Lythgoe D; de Azambuja E; Beresford M; Howell SJ
    Oncotarget; 2016 Mar; 7(11):13209-20. PubMed ID: 26334099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
    Gullo G; Walsh N; Fennelly D; Bose R; Walshe J; Tryfonopoulos D; O'Mahony K; Hammond L; Silva N; McDonnell D; Ballot J; Quinn C; McDermott EW; Evoy D; Prichard R; Geraghty J; Amstrong J; Crown J
    Br J Cancer; 2018 Aug; 119(3):374-380. PubMed ID: 29773838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial.
    Kaidarova D; Zhavrid E; Shatkovskaya O; Prokharau A; Akhmed N; Sembayev D; Rutzhanova Z; Ivankov A
    Cancer Treat Res Commun; 2024; 40():100817. PubMed ID: 38735220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.
    Ignatiadis M; Litière S; Rothe F; Riethdorf S; Proudhon C; Fehm T; Aalders K; Forstbauer H; Fasching PA; Brain E; Vuylsteke P; Guardiola E; Lorenz R; Pantel K; Tryfonidis K; Janni W; Piccart M; Sotiriou C; Rack B; Pierga JY
    Ann Oncol; 2018 Aug; 29(8):1777-1783. PubMed ID: 29893791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.
    Papakonstantinou A; Matikas A; Bengtsson NO; Malmström P; Hedayati E; Steger G; Untch M; Hübbert L; Johansson H; Hellström M; Gnant M; Loibl S; Greil R; Moebus V; Foukakis T; Bergh J
    Cancer; 2020 Mar; 126(6):1175-1182. PubMed ID: 31851385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.
    Gligorov J; Curigliano G; Müller V; Knoop A; Jenkins V; Verma S; Osborne S; Lauer S; Machackova Z; Fallowfield L; Pivot X
    Breast; 2017 Aug; 34():89-95. PubMed ID: 28549309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
    Inno A; Barni S; Ghidini A; Zaniboni A; Petrelli F
    Breast Cancer Res Treat; 2019 Jan; 173(2):247-254. PubMed ID: 30317424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
    Hiller L; Dunn JA; Loi S; Vallier AL; Howe DL; Cameron DA; Miles D; Wardley AM; Earl HM
    BMC Cancer; 2018 Apr; 18(1):391. PubMed ID: 29621991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
    Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.